Jonathan Lucas
Brentwood, California, United States
8K followers
500+ connections
8K followers
500+ connections
About
Possess 25+ years’ successful, progressive strategic IT experience including defining…
Activity
-
To mark the recent closing of its $144 million public offering, Zura Bio Limited (Nasdaq: ZURA) was recognized on the Nasdaq Tower in Times…
To mark the recent closing of its $144 million public offering, Zura Bio Limited (Nasdaq: ZURA) was recognized on the Nasdaq Tower in Times…
Liked by Jonathan Lucas
-
We’re delighted to welcome Tom Witt to Eyconis as Vice President of Business & Corporate Development. Tom brings more than 20 years of experience…
We’re delighted to welcome Tom Witt to Eyconis as Vice President of Business & Corporate Development. Tom brings more than 20 years of experience…
Liked by Jonathan Lucas
Experience
-
GNI Biomaterials Group-Berkeley Advanced Biomaterials & Berkeley Biologics
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
More activity by Jonathan
-
Systemic sclerosis (#SSc), also known as scleroderma, is a rare, heterogeneous, and complex rheumatic autoimmune disease that can affect the skin…
Systemic sclerosis (#SSc), also known as scleroderma, is a rare, heterogeneous, and complex rheumatic autoimmune disease that can affect the skin…
Liked by Jonathan Lucas
-
Leaving #JPM26 and San Francisco with a clear conviction: biopharma will continue to accelerate, driven by the scale of unmet medical needs and major…
Leaving #JPM26 and San Francisco with a clear conviction: biopharma will continue to accelerate, driven by the scale of unmet medical needs and major…
Liked by Jonathan Lucas
-
Yesterday, we celebrated our successful IPO by ringing theb Nasdaq Closing Bell! This was a proud milestone for LB Pharmaceuticals. It reflects our…
Yesterday, we celebrated our successful IPO by ringing theb Nasdaq Closing Bell! This was a proud milestone for LB Pharmaceuticals. It reflects our…
Liked by Jonathan Lucas
-
We are excited to present preliminary data from the Phase 1 study of our investigational ENPP3 x CD3 bispecific antibody, XmAb819, in patients with…
We are excited to present preliminary data from the Phase 1 study of our investigational ENPP3 x CD3 bispecific antibody, XmAb819, in patients with…
Liked by Jonathan Lucas
-
I am thrilled to be invited as a coach at the Healthcare Businesswomen’s Association 2025 Annual Conference—a can’t-miss event that brings together…
I am thrilled to be invited as a coach at the Healthcare Businesswomen’s Association 2025 Annual Conference—a can’t-miss event that brings together…
Liked by Jonathan Lucas
-
Today Atara announced that the FDA has accepted its Biologics License Application (BLA) Resubmission with a Priority Review and a #PDUFA target…
Today Atara announced that the FDA has accepted its Biologics License Application (BLA) Resubmission with a Priority Review and a #PDUFA target…
Liked by Jonathan Lucas
-
📢 Pierre Fabre Pharmaceuticals (USA) announces Transfer of Investigational New Drug Application for tabelecleucel from Atara Biotherapeutics, Inc.…
📢 Pierre Fabre Pharmaceuticals (USA) announces Transfer of Investigational New Drug Application for tabelecleucel from Atara Biotherapeutics, Inc.…
Liked by Jonathan Lucas
-
We are excited to announce the appointment of Eric Hyllengren as Zura Bio’s Chief Financial Officer! Eric brings extensive financial leadership…
We are excited to announce the appointment of Eric Hyllengren as Zura Bio’s Chief Financial Officer! Eric brings extensive financial leadership…
Liked by Jonathan Lucas
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content